medigraphic.com
Colegio de Medicina Interna de México.

2012, Número 3

<< Anterior Siguiente >>

Med Int Mex 2012; 28 (3)


El paciente adulto con fenilcetonuria: un nuevo reto para el médico internista en México

Arcos-Correa JH, Vela-Amieva M

Idioma: Español
Referencias bibliográficas: 48
Paginas: 256-261
Archivo PDF: 356.95 Kb.


RESUMEN

Los errores innatos del metabolismo (EIM) están considerados como enfermedades esencialmente pediátricas pero actualmente, gracias a los avances médicos, las cohortes de estos pacientes pediátricos están sobreviviendo y alcanzando la adolescencia y la edad adulta. La transición de su atención en la clínica pediátrica a la clínica de adultos implica nuevos retos para los internistas. El objetivo de este artículo es actualizar y dar a conocer, dentro de la comunidad de internistas, algunas de las características de la fenilcetonuria (PKU), uno de los EIM de los aminoácidos más frecuente, resaltando sus principales complicaciones en los pacientes adultos así como algunas recomendaciones para su correcta atención.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Ellaway C, Wilcken B, Chistodoulou J. Clinical approach to inborn errors of metabolism presenting in the newborn period. J Paediatr Child Health 2002;38:511-517.

  2. Lee PJ. Growing older: the adult metabolic clinic. J Inherit Metab Dis 2002;25:252-60.

  3. Vela-Amieva M, Belmont-Martínez L, Fernándaez-Lainez C, Ramírez-Frías C, Ibarra-González I. Frecuencia de enfermedades metabólicas congénitas susceptibles de ser identificadas por el tamiz neonatal. Acta Pediatr Méx 2009;30:156-162.

  4. Scriver CR, Kaufman S. Hyperphenylalaninemia: Phenylalanine hydroxylase deficiency. En: Scriver CR, Beaudet AL, Valle D, eds. The metabolic and molecular basis of inherited disease. 8th ed. New York, NY: McGraw-Hill Inc, 2001. pp. 1667-1724.

  5. Blau N, van Spronsen FJ, Levy H. Phenylketonuria. Lancet 2010;376:1417-1427.

  6. Blau N, Bonafé L, Blaskovics M. Disorders of phenylalanine and tetrahydrobiopterin metabolism. En Blau N, Duran M, Blaskovics M, Gibson KM, eds. Physicians’ guide to the laboratory diagnosis of metabolic disease. Heidelberg: Springer, 2005. pp. 89-106.

  7. Cederbaum S. Phenylketonuria: an update. Curr Opin Pediatr 2002;14:702-706.

  8. Enns GM, Packman W. The adolescent with an inborn error of metabolism: medical issues and transition to adulthood. Adolesc Med. 2002;13:315-329.

  9. Lee PJ, www.ommbid.com. Chapter 5S. The adult patient with hereditary metabolic disease. Accesed 29/07/2011.

  10. Pitt DB, Danks DM. The natural history of untreated phenylketonuria over 20 years. J Paediatr Child Health 1991;27:189-190.

  11. Hoeksma M, Reijngoud DJ, Pruim J, de Valk HW, Paans AM, van Spronsen FJ. Phenylketonuria: high plasma phenylalanine decreases cerebral protein synthesis. Mol Genet Metab 2009;96:177-182.

  12. Hörster F, Schwab MA, Sauer SW, Pietz J, Hoffmann GF, Okun JG, et al. Phenylalanine reduces synaptic density in mixed cortical cultures from mice. Pediatr Res 2006;59:544-548.

  13. Martynyuk AE, Glushakov AV, Summers C, Laipis PJ, Dennis DM, Seubert CN. Impaired glutamatergic synaptic transmission in the PKU brain. Mol Genet Metab 2005;86:34-42.

  14. Shefer S, Tint GS, Jean-Guillaume D, Daikhin E, Kendler A, Nguyen LB, et al. Is there a relationship between 3-hydroxy- 3-methylglutaril coenzyme a reductase activity and forebrain pathology in the PKU mouse? J Neurosci Res 2000;61:549-563.

  15. Ghozlan A, Varoquaux O, Abadie V. Is monoamine oxidase-B a modifying gene and phenylethylamine a harmful compound in phenylketonuria? Mol Genet Metab 2004;83:337-340.

  16. Ribas GS, Sitta A, Wajner M, Vargas CR. Oxidative stress in phenylketonuria: what is the evidence? Cell Mol Neurobiol 2011;31(5):653-662.

  17. Hommes FA, Moss L. Myelin turnover in hyperphenylalaninaemia. A re-evaluation with the HPH-5 mouse. J Inherit Metab Dis 1992;15:243-251.

  18. van Spronsen FJ, de Groot MJ, Hoeksma M, Reijngoud DJ, van Rijn M. Large neutral amino acids in the treatment of PKU: from theory to practice. J Inherit Metab Dis 2010;33(6):671-676.

  19. Etzel MR. Manufacture and use of dairy protein fractions. J Nutr 2004;134:S996-1002.

  20. Guillén-López S, Vela-Amieva M. Actualidades en el manejo nutricional de la fenilcetonuria. Acta Pediatr Mex 2011;32:107-114.

  21. Burton BK, Nowacka M, Hennermann JB, Lipson M, Grange DK, Chakrapani A, et al. Safety of extended treatment with sapropterin dihydrochloride in patients with phenylketonuria: Results of a phase 3b study. Mol Genet Metab 2011;103(4):315-322.

  22. Weglage J, Fünders B, Wilken B, Schubert D, Ullrich K. School performance and intellectual outcome in adolescents with phenylketonuria. Acta Paediatr 1993;82(6-7):582-586.

  23. Waisbren SE, Brown MJ, de Sonneville LM, Levy HL. Review of neuropsychological functioning in treated phenylketonuria: an information processing approach. Acta Paediatr 1994;40(7):98-103.

  24. Schmidt E, Rupp A, Burgard P, Pietz J, Weglage J, de Sonneville L. Sustained attention in adult phenylketonuria: the influence of the concurrent phenylalanine-blood-level. J Clin Exp Neuropsychol 1994;16(5):681-688.

  25. Cleary MA, Walter J.H, Wraith JE, Alani S.M, Whittle D , Jenkins J.P.R, Tyler K. Magnetic resonance imaging of the brain in phenylketonuria. Lancet 1994;344(8915):87-90.

  26. Joseph B, Dyer CA Relationship between myelin production and dopamine synthesis in the PKU mouse brain. J Neurochem 2003;86(3):615-626.

  27. ten Hoedt AE, de Sonneville LM, Francois B, ter Horst NM, Janssen MC, Rubio-Gozalbo ME, Wijburg FA, Hollak CE, Bosch AM. High phenylalanine levels directly affect mood and sustained attention in adults with phenylketonuria: a randomised, double-blind, placebo-controlled, crossover trial. J Inherit Metab Dis 2011;34:165-171.

  28. Hoeks MPA, den Heijer M, Janssen MCH. Adult issues in phenylketonuria. Netherlands J Med 2009;67:2-7.

  29. Brenton DP, Pietz J. Adult care in phenylketonuria and hyperphenylalaninaemia: the relevance of neurological abnormalities. Eur J Pediatr 2000;159(Suppl 2):S114-S120.

  30. Paine RS. The variability in manifestations of untreated patients with phenylketonuria (phenylpyruvic aciduria). Pediatrics 1957;20(2):290-302.

  31. Baumeister AA, Baumeister AA. Dietary treatment of destructive behavior associated with hyperphenylalaninemia. Clin Neuropharmacol 1998;21(1):18-27.

  32. Koch R, Burton B, Hoganson G, Peterson R, Rhead W, Rouse B,et al. Phenylketonuria in adulthood: a collaborative study. J Inherit Metab Dis 2002;25(5):333-346.

  33. Waisbren SE, Levy HL. Agoraphobia in phenylketonuria. J Inherit Metab Dis 1991;14:755-764.

  34. Güttler F, Lou H. Dietary problems of phenylketonuria: effect on CNS transmitters and their possible role in behaviour and neuropsychological function. J Inherit Metab Dis 1986;9(Suppl 2):169-177.

  35. Koch R, Moseley KD, Yano S, Nelson M Jr, Moats RA. Large neutral amino acid therapy and phenylketonuria: a promising approach to treatment. Mol Genet Metab 2003;79(2):110-113.

  36. Robinson M, White FJ, Cleary MA, Wraith E, Lam WK, Walter JH. Increased risk of vitamin B12 deficiency in patients with phenylketonuria on an unrestricted or relaxed diet. J Pediatr 2000; 136:545-7.

  37. Hvas AM, Nexo E, Nielsen JB. Vitamin B12 and vitamin B6 supplementation is needed among adults with phenylketonuria (PKU). J Inherit Metab Dis 2006;29:47-53.

  38. Miller D, Specker B, Ho M, Norman E. vitamin B12 status in a macrobiotic community. Am J Clin Nutr 1999;53:524-529.

  39. Casanueva E, Fernández-Gaxiola AC. Vitamina B12. En Bourges H, Casanueva E, Rosado JL. Recomendaciones de ingestión de nutrimentos para la población mexicana. Bases fisiológicas. Ciudad de México: Editorial Panamericana, 2005. pp 151-161.

  40. Ames BN. Micronutrient deficiencies. A mayor cause of DNA damage. Ann NY Sci 1999;889:87-106.

  41. Lindenbaum J, Rosenberg IH, Wilson PWF,Stabler SP, Allen RH. Prevalence of cobalamin deficiency in the Framingham ederly population. Am J Clin Nutr 1994;60:2-11.

  42. Wright JD, Bialostosky K, Gunter EW, Carroll MD, Najjar MF, Bowman BA, Johnson CL. Blood folate and vitamin B12: United States, 1988-94. Vital Health Stat 11 1998;243:1-78.

  43. Modan-Moses D, Vered I, Schwartz G, Anikster Y, Abraham S, Segev R, Efrati O.Peak bone mass in patients with phenylketonuria. J Inherit Metab Dis. 2007;30(2):202-208.

  44. Pérez-Dueñas B, Cambra FJ, Vilaseca MA, Lambruschini N, Campistol J, Camacho JA. New approach to osteopenia in phenylketonuric patients. Acta Paediatr 2002;91(8):899-904.

  45. Lee PJ, Lilburn M, Baudin J. Maternal phenylketonuria: experiences from the United Kingdom. Pediatrics 2003;112:1553-1556.

  46. Commitee on genetics. Maternal phenylketonuria. Pediatrics 2008;122:445-449.

  47. Gambol PJ. Maternal phenylketonuria síndrome and case management implications . J Pediatr Nurs 2007;22:129-138.

  48. Levy HL, Ghavami M. Maternal phenylketonuria: a metabolic teratogen. Teratology 1996;53:176-184.




2020     |     www.medigraphic.com